Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

摘要: Non-small-cell lung cancer (NSCLC) is a leading cause of malignancy-related mortality in the Western world. Despite advances early detection and standard treatment, NSCLC frequently diagnosed at an advanced stage therefore patients have poor prognosis. However, its heterogeneity provides ample opportunity for multiple treatment approaches target pathways. Considerable progress has been made identifying novel targets, to growing number options. Overall survival (OS) may not always be most appropriate primary end point assessment efficacy, as it likely that with will receive lines therapy during their treatment. Additionally, crossover appears ethical necessity many investigators if molecular targeted agents display outstanding efficacy. While improving OS remains goal clinicians, progression-free (PFS) increasingly being utilised alternative point. In this article, we evaluate value PFS measure efficacy NSCLC, compare clinical situation other solid malignancies review options NSCLC.